Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

How Risky Is Ocugen After Its Recent Setback?

TheMotleyFool

0 0

How Risky Is Ocugen After Its Recent Setback?Photo, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

Investors cheered on Ocugen (NASDAQ: OCGN) earlier this year when it signed a deal to co-commercialize Bharat Biotech's vaccine candidate in the U.S. The company recently abandoned the idea of a quick authorization, though. In this Motley Fool Live video recorded on June 22, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss what happened -- and what this means for the stock.

Source Fool.com

Like: 0

OCGN

Share